cms.bioaccessla.com

Tag: argentina

  • ICH E6(R3) Annex 2 Just Hit Step 4 In Rio. Argentina Is Positioned To Be Latin America’s First Adopter. Here’s What That Means For Medtech Sponsors.

    On June 3, 2026, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use convened its biannual Assembly in Rio de Janeiro — the first ICH meeting ever held in Latin America. Brazil’s health regulator, ANVISA, hosted. Among the multiple guidelines under consideration at the meeting, only one was advanced to Step 4 — the final stage of ICH adoption: E6(R3) Annex 2, the guideline that codifies decentralized clinical trial design, pragmatic study architectures, digital health technologies, and real-world data as integral elements of GCP-compliant clinical research.

    For a Latin American clinical research operator that has spent the past sixteen years arguing the case to MedTech, biotech, and radiopharma founders, the June 1 to June 4 sequence in Rio is the most strategically significant positioning event of 2026. The geographic precedent is itself meaningful — ICH governance has historically convened in Geneva, Brussels, Tokyo, or other established regulatory capitals. Selecting Rio de Janeiro and partnering with ANVISA as host signals a structural shift in how ICH governance views Latin American regulatory infrastructure. The substantive outcome — only one guideline elevated to Step 4 at the meeting, and that guideline being the one that defines modern trial design — matters even more for how sponsors will think about LATAM site sequencing over the next 18 to 24 months.

    This post unpacks what Annex 2 actually changes, why the Rio venue matters, and how MedTech sponsors should think about Argentina’s position as the first Latin American jurisdiction structurally ready to accept Annex 2-compliant protocols without amendment.

    What ICH E6(R3) Annex 2 Actually Changes

    ICH E6(R3) is the current Good Clinical Practice (GCP) guideline that all major regulators — FDA, EMA, MHRA, PMDA, Health Canada, and adopting regulators in Latin America — converge on for clinical trial conduct. The most recent revision moved GCP to a risk-based, principle-driven model. Annex 2 extends E6(R3) to explicitly cover the trial designs that have become operational reality over the past five years but lacked formal codification in GCP guidance.

    Specifically, Annex 2 addresses:

    • Decentralized clinical trials (DCTs) — trials where participant interaction with study sites is partially or fully replaced by remote visits, home-based assessments, mobile health units, or telehealth consultations.
    • Pragmatic trial designs — protocols built around real-world clinical settings, with broader patient populations and less restrictive inclusion criteria than traditional efficacy trials.
    • Remote site visits — sponsor monitoring conducted through electronic data review, remote source verification, and risk-based on-site oversight rather than universal in-person visits.
    • Digital health technology (DHT) data capture — continuous glucose monitors, wearable cardiac telemetry, accelerometer-based motion data, smartphone-based patient-reported outcomes, and similar tools used as primary or secondary endpoint capture methods.
    • Real-world data (RWD) — use of electronic health records, claims data, registries, and other non-trial sources as supporting evidence within GCP-compliant studies.
    • Adaptive designs — pre-specified protocol modifications based on accumulating trial data, including sample size re-estimation and arm-dropping decisions.

    The substantive shift in Annex 2 is not new regulation. It is the formal incorporation of these design elements into GCP rather than treating them as exceptions that require special justification. For sponsors who have been building modern trial designs over the past five years, the legal architecture finally caught up with the operational reality.

    Why The Rio Venue Matters

    ICH Assembly meetings rotate among the home jurisdictions of ICH members. Hosting the meeting is a substantive role — the host regulator coordinates logistics, sets the agenda for site-specific discussions, and shapes the framing of how the meeting’s outcomes are communicated to global stakeholders. ANVISA hosting the June 2026 Assembly is the strongest signal to date that Brazilian regulatory infrastructure is converging with ICH governance not as an observer but as an active participant.

    For Brazilian sponsors and CROs, the immediate implication is that ANVISA’s preparation for formal E6(R3) adoption is now visible in a way it was not six months ago. The May 28, 2026 ANVISA board session that explicitly addressed ICH E6 and E8 implementation preparation was the first concrete signal. The June 3 Assembly hosting is the next, much stronger signal. Brazilian formal E6(R3) adoption has no publicly announced timeline yet, but the operational trajectory is no longer in doubt.

    For Argentina, the implication is different but equally substantive. Argentina’s ANMAT, under Disposición 7516/25 operative since December 1, 2025, already maintains a regulatory framework aligned with E6(R3) principles. Argentina did not need to host the Rio Assembly to be ready for Annex 2 — it was already there. What the Rio Assembly does for Argentina is confirm that its regulatory positioning was correctly anticipated, and accelerate the speed at which ANMAT can absorb Annex 2-aligned protocols from sponsors.

    Argentina As The First LATAM Annex 2-Ready Jurisdiction

    Disposición 7516/25 modernized Argentina’s clinical trial framework along several dimensions that align directly with E6(R3) principles: a 62-day parallel ethics and agency review pathway, ICH E6(R3) substantive alignment in protocol structure expectations, and operational mechanisms for risk-based monitoring and remote oversight. Critically for Annex 2, Disposición 7516/25 does not preclude decentralized design elements, DHT data capture, or pragmatic patient populations — it accommodates them.

    The practical consequence is that sponsors designing Annex 2-compliant protocols for FDA or EMA submission in 2026 and 2027 do not face a structural barrier to LATAM site inclusion when Argentina is the lead LATAM jurisdiction. Brazil, Colombia, Mexico, and other LATAM regulators have not formally adopted E6(R3), let alone Annex 2 — meaning protocols built around decentralized or DHT-enabled designs face higher regulatory friction in those jurisdictions until each regulator adopts the guidance domestically.

    For Brazil, the trajectory is unambiguous post-Rio. ANVISA hosting the Assembly, the May 28 board session on E6 and E8 preparation, and the substantive operational alignment between ANVISA’s technovigilance and clinical research frameworks all point toward formal E6(R3) adoption in 2026 or 2027. Annex 2 acceptance follows.

    For Mexico (COFEPRIS), Colombia (INVIMA), and other LATAM regulators, the path is less defined. Colombia’s pending Decreto Único de Dispositivos Médicos e In Vitro (currently in WTO comment phase with a July 17 deadline) introduces international reliance pathways that may indirectly accelerate Annex 2 acceptance, but no formal adoption has been signaled.

    Operational Implications For MedTech Sponsors Designing 2026-2027 Protocols

    For a MedTech sponsor designing a protocol today for a 12 to 18 month FIH-to-pivotal sequence, three operational questions matter immediately.

    First, should the protocol be built Annex 2-compliant from the start? The answer is almost always yes if any of the following apply: DHT-collected endpoints are part of the endpoint set; the patient population is large enough that pragmatic design considerations would materially expand enrollment; remote visits or telehealth consultations would meaningfully reduce participant burden; or the trial design contemplates pre-specified adaptive elements such as sample size re-estimation. Building Annex 2-compliant from the start adds modest protocol-authoring effort and substantial future flexibility.

    Second, how should LATAM country sequencing change? For 2026 and through Q2 2027, Argentina-primary is now the recommended LATAM lead jurisdiction for any Annex 2-aligned design. Disposición 7516/25 is the only operative LATAM framework that can absorb the design without amendment. Brazil-secondary is appropriate as ANVISA formalizes its adoption. Mexico and Colombia remain opportunistic, evaluated on therapeutic-area depth and sponsor-specific operational requirements rather than as primary LATAM hubs for decentralized designs.

    Third, what about sponsors with existing LATAM site relationships built around traditional trial architectures? The Annex 2 guidance does not invalidate traditional trial designs. Sponsors running fully on-site, non-decentralized protocols can continue without adjustment. The shift matters for sponsors whose product strategy is built around DHT-collected endpoints or decentralized data capture — for whom the regulatory architecture in LATAM was previously a bottleneck and now is not.

    What Comes Next

    National regulator implementation of E6(R3) Annex 2 will proceed on independent timelines through 2026 and 2027. FDA has signaled implementation guidance is forthcoming. EMA has indicated alignment without formal adoption schedule. PMDA and Health Canada are expected to follow. In Latin America, ANMAT is positioned to be the first formal adopter, followed by ANVISA. The realistic timeline for ANMAT formal Annex 2 acceptance is Q4 2026 to Q1 2027. ANVISA follows in H1 2027 to H2 2027.

    For sponsors making 2026 country sequencing decisions today, the implication is straightforward. Argentina is positioned as the natural lead LATAM jurisdiction for Annex 2-aligned protocols. Brazil follows. Mexico and Colombia continue to be evaluated case-by-case based on therapeutic-area depth and sponsor-specific requirements.

    The Bottom Line

    Latin America is no longer at the edge of global GCP. The June 3 Rio Assembly, the ANVISA hosting of the meeting, and the Step 4 advancement of E6(R3) Annex 2 together signal a structural shift that sponsors building modern trial designs should integrate into 2026-2027 strategy now rather than after the fact.

    The most expensive country sequencing decision is not the one made wrong. It is the one made too late, after the trial design has been frozen and the regulatory pathway is already constrained by choices that no longer reflect the current landscape.

    If you are evaluating an Annex 2-aligned FIH protocol for 2026 or 2027 and want a LATAM country sequencing analysis that integrates the new Rio Assembly outcomes, the team at bioaccess® can produce a tailored proposal within two weeks. We have run first-in-human and pivotal-stage trials across Argentina, Brazil, Colombia, Mexico, and Panama since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • $8 Billion Of Pharma Capital Just Pointed At Argentina. What Medtech Founders Should Take From The May 29 CAEME Announcement.

    On May 29, 2026, the Cámara Argentina de Especialidades Medicinales (CAEME) announced jointly with President Javier Milei a six-year clinical research investment commitment from seven multinational pharmaceutical companies: Pfizer, Merck, Roche, Novartis, BMS, GSK, and Sanofi. The total commitment is USD 8 billion through 2032. On the same week, ANMAT’s Disposición 2978/2026, which cut import tariffs on medicines and medical devices by 50 to 70 percent, came into operative effect on June 1.

    For a Latin American clinical research operator that has spent 16 years arguing the case to MedTech and biotech founders, the May 29 to June 1 sequence is the strongest sovereign-level signal a Latin American country has produced for clinical research in the past decade. The data and the policy arrived in the same week. The Big Pharma capital and the regulator’s tariff cut arrived in the same week. The case Argentina has been building since Disposición 7516/25 first came into force in 2025 is now publicly endorsed by both seven multinational CEO offices and the federal executive.

    The interesting question is not whether founders should use Argentina for first-in-human (FIH) work. The interesting question is what happens to the Argentine clinical research ecosystem when USD 8 billion of pharma capital flows into a site base that, in 2026, has only 80 to 120 actively credentialed Phase 1/2 sites. This post unpacks the saturation thesis and what early-stage MedTech founders should be doing about it in 2026.

    The Site Saturation Math

    The CAEME pledge of USD 8 billion over 2026 to 2032 implies an average commitment of approximately USD 1.33 billion per year. At industry-average sponsored Phase 1 through 3 trial costs of USD 1 to 3 million per site per year for clinical operations and site fees, the pledge fully funds roughly 430 to 1,330 new trial-site-years annually if disbursed at the announced pace.

    Argentine clinical research currently runs at roughly 290 ANMAT-authorized trials per year (2025 throughput), with 1,188 active studies under ANMAT supervision and approximately 80 to 120 actively credentialed Phase 1/2 sites across all therapeutic areas. The pledge contemplates a 2.5x step-up in trial inflows against approximately the same site base.

    The implication is straightforward. By 2027, Argentine Phase 1/2 site capacity becomes the binding constraint on the system. Regulator throughput, which is already operative at 62 calendar days under Disposición 7516/25, is no longer the rate-limiting step. Site availability is. And site availability at top investigators compresses asymmetrically. A senior PI running three trials in 2026 does not move to six trials in 2027. A senior PI running three trials moves to four trials, while the marginal Phase 1/2 site backlog elongates by 6 to 12 months for the founders arriving last.

    Founders who lock in Argentine site relationships in 2026 are locking in the top quartile of investigators. Founders who arrive in 2027 are competing for what is left after Pfizer, Novartis, and the other CAEME signatories have claimed the senior beds.

    Why the Argentine Government Did This Now

    Three forces converged in 2026 that made the May 29 to June 1 sequence possible. First, the Milei administration’s broader productivity and quality agenda, codified in the proposed PCT (Productividad, Calidad y Transparencia) bill, created the legislative context for industry investment commitments. Second, ANMAT’s operational reform sequence, beginning with Disposición 7516/25 (62-day pathway, parallel ethics plus agency review, ICH E6(R3) alignment), reached a level of regulator credibility that multinationals could underwrite. Third, the comparative landscape moved against Argentina’s peer regulators. Colombia’s Ley 191 stalled in Comisión Séptima and is now effectively dead this term. Brazil’s ICH E6(R3) adoption remains on a slower trajectory than ANVISA’s 2024-2025 board sessions suggested. Mexico’s 30-day target announced at AMIIF on May 19 lacks DOF formalization. Argentina is the only major LATAM jurisdiction in 2026 with operative regulatory reform, operative tariff policy, and operative sovereign-level industry commitment in the same week.

    The PCT bill is the only caveat that matters. The CAEME pledge is contingent on PCT passage. As of June 1, the bill remains stalled. Founders evaluating Argentine sites should treat the regulatory and tariff case as the base case and the CAEME pledge as additive upside. Disposición 7516/25 and Disposición 2978/2026 are in force regardless.

    How to Sequence Argentina in 2026

    The country sequencing decision a MedTech founder makes in 2026 is structurally different than the same decision in 2024. Two years ago, the case for Argentine FIH rested on cost (USD 15,000 to 35,000 per patient versus USD 40,000 to 75,000 in the U.S. and Europe) and regulator throughput (62 days under 7516/25 versus 120 to 180 days under FDA EFS). Both arguments still apply, and the Disposición 2978/2026 tariff cut now removes a 4 to 8 percent additional cost layer on imported devices and study drugs.

    What is new in 2026 is the time pressure. The CAEME pledge does not change the operational case. It changes the urgency of the operational case. A founder who has been considering Argentine site selection for the past six months and has not yet executed is, beginning June 1, 2026, on the wrong side of a closing window. By Q4 2026, the same site relationships will be visibly competitive. By Q2 2027, the top-quartile PI list will be substantively claimed.

    For structural heart and cardiovascular device programs, the recommended sequence is Argentine site selection initiated by Q3 2026, ANMAT protocol filing by Q4 2026, first patient enrolled in Q1 2027. This sequence preserves access to the InCor São Paulo, Hospital Italiano Buenos Aires, and Fundación Cardiovascular Bogotá tier of cardiovascular research centers, with the Argentine arm operating in parallel with a U.S. EFS submission.

    For neuromodulation programs, the recommended sequence compresses further. Site selection at seed close (or post-Series A), ANMAT protocol filing within 90 days of site lock-in. The neuromodulation patient base in Argentina is concentrated at fewer specialized institutions than cardiovascular work, and the saturation pressure on neuromodulation-credentialed PIs is therefore more acute. Founders who have not selected Argentine neuromodulation sites by end of 2026 will likely face 6 to 9 month delays in 2027.

    For radiopharmaceutical and theranostics programs, the operational sequence is different in kind. Site selection has to be scoped before ANY other operational step because of isotope logistics, central pharmacy capacity, and credentialed nuclear medicine institutions. Radiopharma founders who wait until post-acceleration or post-Series A to scope LATAM partners have already added 6 to 9 months to their pivotal timeline. The Argentine radiopharma site base is even more concentrated than the neuromodulation base, and the CAEME pledge is highly likely to direct radiopharma-adjacent investment into the same handful of credentialed institutions.

    What This Means for the Colombia Case

    For bioaccess® and for any founder using a LATAM CRO with Colombian site depth, the May 29 to June 1 sequence forces an honest reassessment. Colombia in 2026 holds the following: established U.S.-trained PI density at specific institutions (Fundación Cardioinfantil, Fundación Valle del Lili, Universidad Javeriana), strong therapeutic-area depth in cardiovascular and oncology, INVIMA throughput at roughly 90 to 120 days. Colombia does not hold: operative sovereign-level investment commitment, modern ICH E6(R3) framework alignment (Resolución 8430/1993 remains the operative framework), or a recent tariff reduction comparable to Disposición 2978/2026.

    The Colombia case for 2026 is no longer “cheaper and faster.” The Colombia case is “specific therapeutic-area depth, U.S.-trained PI networks, and complementarity to an Argentine arm.” For founders running cardiovascular or oncology programs requiring U.S. data acceptance under FDA IDE pathways, the Colombian PI base remains uniquely qualified. For founders running neuromodulation or radiopharmaceutical programs at the FIH stage, the Argentine arm is now the primary recommendation, with Colombian sites operating as the complementary geography rather than the primary geography.

    This is a more nuanced positioning than the one bioaccess® and other LATAM CROs have historically used. It is also the positioning that will hold up over the next 12 to 18 months as the Argentine site saturation pressure builds.

    What Founders Should Do Before End of Q3 2026

    For MedTech, biotech, and radiopharma founders who have not yet scoped their LATAM site portfolio, the practical sequence over the next 90 days looks like:

    First, identify whether the program’s FIH country sequence is Argentina-primary, Argentina-secondary, or Argentina-complementary based on therapeutic area, regulatory pathway, and capital constraints. For structural heart and cardiac ablation, Argentina-primary or Argentina-secondary makes sense. For neuromodulation, Argentina-primary. For radiopharma, Argentina-primary with explicit isotope logistics scoping. For oncology devices with U.S. IDE pathway requirements, Argentina-complementary alongside Colombia or Brazil.

    Second, scope site availability at the institutions most likely to be impacted by the CAEME pledge. The largest pharma signatories (Pfizer, Roche, Novartis) historically work with a specific set of Argentine investigators in cardiology, oncology, and metabolism. Site availability at those investigators will compress first.

    Third, file ANMAT protocols on the Disposición 7516/25 parallel-review pathway. The 62-day timeline allows a 2026 Q3 site selection to produce first-patient-in by year-end. Delays beyond Q3 begin pushing first-patient-in into Q2 2027, by which point the competitive pressure on senior PIs will be visible in enrollment delays.

    Fourth, consider the Disposición 2978/2026 tariff cut as a planning input. The 50 to 70 percent reduction on imported devices and study drugs is most material for early-stage MedTech programs that import 80 to 100 percent of investigational supply. Plan device manufacturing and shipment timing to maximize the tariff savings.

    The Bottom Line

    Argentina did not become a clinical research hub on May 29, 2026. Argentina has been a clinical research hub for 30 years. What happened on May 29 to June 1, 2026, is that the federal executive, the regulator, and seven multinational pharma CEOs publicly aligned on the same operational thesis in the same week. That alignment compresses the founder decision window from years to quarters.

    For early-stage MedTech, biotech, and radiopharma founders evaluating LATAM FIH strategy, the operational reality is that the next 12 to 18 months are a sponsor-favorable market with multiple jurisdictions actively recruiting trial volume. Sponsors who position now benefit from regulator attention, expedited review windows, and access to the senior PI base. Sponsors who delay lose that window.

    The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong country sequence for their specific program. Argentina’s May 29 to June 1 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 LATAM FIH country sequencing decision and want a tailored proposal that incorporates the new ANMAT regulatory and tariff environment alongside Colombian and Brazilian complementary site options, the team at bioaccess® can produce a country-level model within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Argentina Just Cut Clinical Trial Import Costs By 50 70%. Here’s What 290 Authorized Trials In 2025 Tell Founders.

    On May 19, 2026, Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) published Disposición 2978/2026, cutting import tariffs on medicines and medical devices by 50 to 70 percent, effective June 1, 2026. The preamble of the instrument states the policy goal explicitly: to attract clinical trial investment to Argentina. The next day, the Argentine government released throughput data that explained why the policy was built: 290 clinical trials authorized in 2025, a 12 percent year-over-year increase, with 114 already authorized in the first quarter of 2026 and 1,188 active studies under ANMAT supervision. Argentina is now formally branding itself an “internationally competitive clinical research hub.”

    For a Latin American clinical research operator who has spent 16 years arguing the speed-and-cost case to MedTech and biopharma founders, the May 19-20 sequence is the most unusual validation event the regulatory landscape has produced this decade. Most LATAM clinical research positioning is CRO marketing. Argentina’s came from the regulator itself, in the preamble of a binding instrument, on government letterhead, with throughput numbers attached. That is not the same kind of evidence as a competitive pitch deck.

    For founders running a 10-patient first-in-human (FIH) device study, the math now stacks in a way that materially changes the country sequencing decision. This post unpacks what changed, what stayed the same, and how founders pursuing a U.S. Early Feasibility Studies (EFS) plus out-of-U.S. (OUS) FIH strategy should think about Argentina in 2026.

    What Changed on May 19, 2026

    Disposición 2978/2026 is the binding instrument. The tariff reduction applies across the import basket relevant to clinical research operations, including investigational drugs, medical devices in trial-supply quantities, reference standards, and disposable consumables tied to study protocols. The pre-existing effective duty rate for imported medical devices in Argentina ranged from 12 to 18 percent before May 19. Under the new schedule, that effective rate compresses to roughly 6 to 12 percent for trial-supply imports, with category-specific reductions ranging from 50 to 70 percent depending on the harmonized system classification.

    On its own, the tariff cut is meaningful. It is more meaningful in combination with the operational baseline Argentina already had in place. Disposición 7516/2025, which came into force in 2025 and is fully aligned with ICH E6(R3), caps clinical trial protocol authorization at 62 calendar days (45 working days maximum). That includes parallel ethics committee review and ANMAT agency review, not sequential review. For comparison, the U.S. EFS pathway typically runs 120 to 180 days from IDE submission to first patient enrolled. Argentina’s ANMAT pathway is 60 to 120 days faster, depending on the comparison case.

    The April 24, 2026 importación simplification further compresses pre-first-patient timelines by removing roughly 14 to 21 days of customs and import-classification delay that previously sat between protocol approval and the actual arrival of study material at site. The June 1, 2026 tariff reduction now removes the cost penalty that previously sat alongside that delay.

    The Throughput Number Most Founders Miss

    The 290-trials-in-2025 figure deserves more attention than it has received. Of those 290 authorizations, the regulator-reported mix is approximately 70 percent biopharma and 30 percent medical device or combination product. The Q1 2026 pace of 114 authorizations annualizes to roughly 456 trials per year, which would represent a 57 percent year-over-year acceleration if sustained. Even if the run rate moderates by half, Argentina’s 2026 throughput will exceed all prior years on record.

    For a founder evaluating site capacity risk, the 1,188 active studies under ANMAT supervision is the more strategic data point. Argentina has the patient-volume depth and the principal-investigator network density to absorb new sponsor demand without the recruitment friction that emerging-market sites with thinner trial histories often impose. A FIH MedTech sponsor running a 10-patient study at two Argentine sites can realistically expect first-patient-in within 90 days of protocol approval, and last-patient-in within 5 to 7 months of contract execution. Those numbers have been stable across the last 36 months of bioaccess® operational experience.

    The Cost Math, Refreshed

    Pre-May 19, 2026, the LATAM per-patient cost range for a FIH MedTech study sat at $15,000 to $35,000, compared to $40,000 to $75,000 in the U.S. and Europe. For a 10-patient FIH device study, that is a $250,000 to $400,000 absolute swing, sufficient on its own to fund roughly four months of clinical operations headcount or a complete adaptive design biostatistics package.

    The June 1 tariff reduction does not move the per-patient labor cost. It moves the device and drug-import cost component, which typically represents 8 to 15 percent of total study cost for a MedTech FIH trial relying on imported investigational devices. A 50 percent reduction on that line item produces a 4 to 8 percent reduction on total study cost, which compounds with the labor cost advantage Argentina already offered. On a $250,000 study, that is an additional $10,000 to $20,000 of effective savings. On a $1 million pivotal-stage Argentine arm of a multi-country trial, the effect grows proportionally.

    The strategic value is not the headline savings number. It is the regulatory clarity that the tariff cut produces. Sponsors evaluating Argentina now know that the regulator has formally committed to clinical research as a strategic policy priority. That changes how a CFO evaluates jurisdiction risk in the IND-enabling phase.

    The Database Anomaly and How to Work Around It

    One operational caveat is worth flagging directly. ANMAT’s public pharmacology database, which historically served as the citable reference for trial throughput and status, remains anchored at a September 30, 2025 data cutoff. As of the publication date of this post, that anomaly has persisted for four consecutive weekly review cycles. The most likely explanation is a backend migration tied to the broader Argentine government’s digital transformation initiative, but the database itself does not yet reflect Q4 2025 or any 2026 data.

    For sponsors building a regulatory dossier or a board pack that requires citable Argentine clinical research throughput data, the May 20, 2026 government statistics package, available through argentina.gob.ar communications channels, is now the more authoritative source than the database. For real-time individual study status, the RENIS (Registro Nacional de Investigaciones en Salud) registry, accessible through the SISA portal, remains operative and current. Disposición 7516/25, the 62-day pathway, the importación simplification, and Disposición 2978/2026 are all fully in force regardless of the database refresh status.

    How to Sequence Argentina in a U.S. EFS Plus OUS FIH Strategy

    The most common 2026 founder question is whether to run U.S. EFS first, OUS FIH first, or both in parallel. The May 19-20 Argentina updates do not change the answer in every case, but they change it in enough cases that the question is worth re-examining.

    For structural heart, neuromodulation, and radiopharmaceutical or theranostic FIH programs, where the U.S. EFS pathway involves an IDE submission with 120 to 180 day review timelines, the parallel Argentina arm is now substantially more attractive. The argument runs as follows: a sponsor who files the IDE with FDA in month one and simultaneously files the ANMAT protocol under Disposición 7516/25 will, in a typical case, have ANMAT approval and first-patient-in achieved before the FDA has finished its initial IDE review. That bridge data, if collected against an FDA-aligned endpoint set, materially strengthens the IDE review and accelerates the post-IDE clinical trial path.

    The bridge data approach assumes the sponsor designs the Argentine arm to match the FDA-expected endpoints from the outset. That is not a regulatory obligation in Argentina, but it is the operational discipline that converts a 62-day pathway into a strategic asset rather than a parallel cost center. ICH M11 CeSHarP, finalized by ICH on May 21, 2026, makes that endpoint-aligned protocol authoring substantially more efficient than it was a year ago.

    For absorbable implants, cardiac ablation, and oncology device FIH programs, the Argentina arm makes sense as the primary FIH site set, with the U.S. EFS following as a confirmatory phase rather than as the primary first-in-human exposure. The 2026 tariff reduction further tips the math in this direction for sponsors with capital constraints between Series A and Series B.

    What This Means for the Latin American Clinical Research Landscape

    Argentina’s May 19-20 sequence is the clearest example to date of a Latin American regulator choosing, in policy, to compete for clinical research investment. Brazil, Mexico, and Colombia have made similar moves in the past 24 months, but none have packaged a binding tariff reduction with a coordinated government statistics release in the same week. The combination is what makes the Argentine moment unusual.

    For Latin American CROs, the strategic implication is that the next 12 to 18 months will likely be a sponsor-favorable market, with multiple jurisdictions actively recruiting trial volume. Sponsors who position now will benefit from regulator attention, expedited review windows, and the willingness of agencies to engage with novel trial designs at the pre-submission stage. Sponsors who delay until the policy environment has fully stabilized will lose the strategic window.

    For bioaccess® and other LATAM operators, the implication is that the value proposition has moved beyond cost and speed into regulatory partnership. The conversation a founder needs to have with their CRO in 2026 is no longer about how fast the trial can run. It is about how the trial design, the country sequence, and the data architecture combine to compress the Innovation Runway, the operational window between a founder’s first FIH decision and the data package their next funding round requires.

    The Bottom Line for Founders

    Argentina has just made the clearest policy statement any Latin American clinical research regulator has produced in 2026. The 62-day pathway under Disposición 7516/25 is operative. The importación simplification is in force. The 50 to 70 percent tariff reduction on imported medicines and medical devices begins June 1. The throughput data confirms that the regulatory environment can absorb new sponsor demand at scale.

    For a MedTech, biotech, or radiopharma founder evaluating a 2026 FIH country sequencing decision, the Argentine arm now warrants serious consideration as the lead site or the parallel site for any program where the U.S. EFS pathway is the comparison baseline. The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong study to run first. Argentina’s May 19-20 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 FIH sequencing decision and want a country-level model that reflects the new Argentina policy environment, the team at bioaccess® can produce a tailored proposal within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Argentina’s $8 Billion Clinical Research Commitment: What It Means For Medtech Startup FIH Trials In 2026

    Argentina’s $8 Billion Clinical Research Commitment: What It Means for MedTech Startup FIH Trials in 2026

    By Julio Martinez-Clark, CEO, bioaccess® | June 2026

    The Signal That Most MedTech Founders Missed

    In late May 2026, seven of the world’s largest pharmaceutical companies — Pfizer, Merck, Roche, Novartis, Bristol Myers Squibb, GSK, and Sanofi — pledged a combined $8 billion in Argentine clinical research investment over the 2026–2032 period. Days later, Argentina’s national drug and food regulator, ANMAT, published Disposición 2978/2026, cutting import tariffs on medicines and medical devices by 50 to 70 percent, effective June 1, 2026.

    The pharma industry picked up the $8 billion figure immediately. MedTech largely did not. That gap is worth examining — because for a structural heart, neuromodulation, or radiopharmaceuticals startup planning a first-in-human (FIH) trial in the next 18 months, these two policy events together represent one of the most significant shifts in the LATAM early-phase clinical research environment in a decade.

    This piece walks through what actually changed, why it matters specifically for device and biotech FIH programs, and how to think about Argentina as part of a first-in-human trial site strategy in 2026.

    What Changed: Disposición 2978/2026 and the $8B Commitment

    The Tariff Reduction

    Disposición 2978/2026 is not a pilot, a phase-in, or a proposed amendment — it is in effect. Import tariffs on medicines and medical devices were reduced by 50 to 70 percent, effective June 1, 2026. For a device company running an FIH feasibility study, this has a direct, calculable effect on budget: investigational devices entering Argentina for clinical use carry materially lower landed cost.

    In early-phase device trials, the investigational product is often the single largest variable cost item outside of site and monitoring fees. A 50 percent reduction in import tariffs on a novel transcatheter device, for example, can change the per-patient cost model meaningfully — particularly for seed-stage and Series A sponsors working with sub-$15 million clinical trial budgets.

    The tariff change also simplifies regulatory logistics. One of the historically cited friction points in Argentine FIH trials has been the import authorization process for investigational devices that were not commercially registered in Argentina. Lower tariff classification, combined with ANMAT’s active throughput cadence, reduces one layer of that friction.

    The $8 Billion Pharma Commitment

    The $8 billion multi-company pledge is not a single infrastructure project — it represents committed clinical research spend across seven major sponsors over six years. The practical implications:

    • Site infrastructure: When Pfizer, Roche, and Novartis are committing multi-year research spend to Argentina, they are investing in investigator networks, clinical infrastructure, and regulatory capacity at sites. This infrastructure — trained investigators, GCP-compliant facilities, ethics committees with high-volume experience — is precisely what a MedTech startup needs for an FIH feasibility study.
    • Regulatory capacity: ANMAT’s workload will increase, but so will its institutional capacity. Regulators that process high volumes of multi-national submissions develop faster, more predictable review cycles. Argentina approved 290 new clinical studies in 2025, an 8 percent year-over-year increase, with more than 1,000 active trials and 50,000+ participants enrolled. The $8 billion commitment is a signal that this trajectory accelerates.
    • International credibility: Large pharma’s visible commitment to Argentina as a clinical research destination reduces the country risk perception that smaller device sponsors sometimes encounter when presenting LATAM FIH data to US investors and regulatory reviewers.

    Practical Considerations for MedTech Sponsors

    A realistic timeline from engagement to first patient for a novel device FIH study in Argentina: Weeks 1–4 site identification; Weeks 5–8 ethics committee; Weeks 6–12 ANMAT authorization; Weeks 10–16 site initiation; Weeks 14–20 first patient in. The Argentina FIH environment also benefits from bioaccess® multi-country capability covering Argentina and Colombia as primary FIH jurisdictions.

    Sources

  • Argentina And Colombia Just Signed A Regulatory Mou. Here’s What That Means For Medtech Sponsors Running Multi-Country LATAM Trials.

    The Headline

    On June 13, 2026, Argentina’s ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) and Colombia’s INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) signed a Memorandum of Understanding that formalizes bilateral cooperation across medicines, food, and medical devices. The text was published on the INVIMA portal the same day. [INVIMA]

    For sponsors running, planning, or sequencing multi-country clinical programs in Latin America, this matters more than the typical regulatory press release. It is the most operationally consequential change to the Argentina-Colombia regulatory interface since 2018 — and it lands at the exact moment Colombia is finalizing its Decreto Único de Dispositivos Médicos and Argentina is operationalizing ICH E6(R3) Annex 2.

    This article walks through what the MoU actually establishes, what it does not establish, and how MedTech and Biopharma sponsors should sequence their LATAM trials in light of it.

    What The MoU Actually Says

    The June 13 instrument is short on legal flourish and dense on operational substance. Stripped to its four working pillars, the MoU establishes:

    1. Information exchange across regulated categories — covering registration dossiers, surveillance signals, and inspection findings.
    2. Protocol and best-practices sharing — methodologies, technical guidance, and procedural alignment on common review pathways.
    3. Joint project collaboration — coordinated capacity-building initiatives, training exchanges, and technical mission programming.
    4. Confidentiality and monitoring framework — formal governance of how shared data is handled and how cooperative activities are tracked over time.

    The cooperation explicitly covers medicines, food, and medical devices. That last category is the one many sponsors miss. The 2014 and 2018 instruments between the two agencies were narrower — 2014 focused on “exchange of experiences and good practices,” and 2018 was specifically about Good Manufacturing Practice inspection records. The 2026 MoU is the first comprehensive framework that unifies the medical device dimension with pharmaceuticals and food under a single working architecture. [ANMAT Cooperation Registry]

    What The MoU Does Not Do

    Three clarifications worth front-loading, because we are already seeing them misunderstood in early secondary commentary.

    The MoU does not create single-window approvals. A sponsor preparing a clinical trial in both Argentina and Colombia still files two separate dossiers, with two separate regulatory teams, on two distinct timelines. ANMAT continues to operate Disposición 7516/25 and the Resolution 1480/2011 ethics framework. INVIMA continues to operate under Decreto 4725 de 2005 and Resolución 1229 de 2013 until the new Decreto Único is published.

    The MoU does not formalize automatic reliance. Reliance — where one regulator can lean on another’s scientific assessment to shorten its own review — exists as a regulatory principle in both agencies’ modernization agendas, but the MoU itself does not create a reliance pathway between them. It creates the plumbing through which such pathways can later be built.

    The MoU does not change cost or fee structures. Sponsors should not expect this instrument to reduce regulatory review fees, ethics committee charges, or local sponsor representation costs in either jurisdiction.

    What It Does, In Practice

    What the MoU does, immediately, is formalize four operational improvements that previously depended on ad-hoc coordination through ICH Assembly hallway conversations and the International Pharmaceutical Regulators Programme (IPRP) plenary sessions.

    One. When a sponsor’s submission triggers a safety signal in one country, that signal can now flow through a structured channel to the other regulator within a defined confidentiality envelope. Before this MoU, a sponsor with a flagged adverse event in Argentina would typically receive an independent inquiry from Colombia weeks or months later, often duplicating the original investigation. After this MoU, the two regulators can coordinate the inquiry’s timing and scope.

    Two. Inspection of a sponsor or manufacturer operating in both jurisdictions can be coordinated. A single inspection mission, with two regulators present or with shared inspection reporting, materially compresses the sponsor’s compliance overhead.

    Three. Capacity-building and training activities — pharmacovigilance, tecnovigilancia, quality risk management — can be conducted jointly. This raises the technical floor in both countries, which is good for sponsors because the predictable downside of trial expansion to a smaller-budget regulator is technical inconsistency at the review level.

    Four. Standards and review methodologies can be aligned over time. The MoU does not specify which standards or methodologies, but it creates the working group structure to negotiate them. The most likely early candidates are software-as-a-medical-device classification, AI/ML model change pathways, and harmonization of IMDRF-aligned UDI requirements.

    The Decreto Único Context

    The MoU lands during one of the most active periods of Colombian medical device regulatory reform in two decades. Colombia’s Decreto Único de Dispositivos Médicos — a 16-chapter, 180-article instrument that consolidates and replaces Decretos 4725/2005 and 3770/2004 — completed its national public consultation phase and entered WTO international consultation on May 18, 2026. The comment window closes July 17, 2026. [CONSULTORSALUD]

    INVIMA’s Director of Medical Devices and Other Technologies, Doris Yolima Gómez Parada, has been publicly explicit about the substantive direction: indefinite-validity authorizations (conditioned on post-market performance), strengthened tecnovigilancia, mandatory Unique Device Identification (UDI) at initial registration, IMDRF-aligned risk classification (three classes expanding to four), and an explicit reliance framework that recognizes FDA, EMA, and ANVISA assessments — supplemented by Pacific Alliance, Rio Accord, and WHO Listed Authority qualifications.

    For a multi-country sponsor, the implication is direct: the Decreto Único modernizes Colombia’s regulatory architecture in ways that are structurally compatible with Argentina’s ICH E6(R3) Annex 2 adoption. The June 13 MoU is the procedural connective tissue between the two modernizations.

    The Argentina Side: ICH Annex 2 Operative

    Argentina entered this MoU from a position of unusual regulatory strength. ANMAT adopted the ICH E6(R3) operative framework under Disposición 7516/25, and Annex 2 — the risk-proportionate quality management addendum — was finalized to Step 4 at the ICH Assembly in Rio de Janeiro on June 3, 2026, two weeks before the MoU was signed. ANMAT confirmed participation in both the ICH Assembly and the IPRP sessions of June 3-4.

    Argentina’s documented FIH timeline benchmark currently sits at 62 days from study start to first patient enrolled, inclusive of ethics committee review, ANMAT regulatory authorization, and clinical site activation. That benchmark assumes a well-prepared sponsor working with operational sites in greater Buenos Aires, La Plata, Mendoza, and Rosario.

    The MoU’s value to an Argentina-primary sponsor is that secondary expansion into Colombia — historically a separate operational track with limited information continuity — now sits on a coordinated information channel. The Decreto Único’s reliance pathway, once operational, can in principle leverage Argentina-generated dossier work for parts of the Colombian submission.

    Practical Implications: How To Sequence A Multi-Country Trial Now

    For a MedTech, Biopharma, or Radiopharma sponsor planning a 2026-2027 LATAM trial, the operational sequencing question changes in three ways.

    Argentina-primary sequencing is now operationally cleaner. If your indication has equivalent patient availability in both Argentina and Colombia, starting in Argentina has three compounding advantages: ICH E6(R3) Annex 2 inspection-readiness, a 62-day study start timeline, and — under the MoU — a smoother information bridge into Colombia for the secondary expansion.

    Colombia is no longer a second-tier choice for sponsors with cardiovascular, oncology, or rare-disease indications. The combination of the MoU plus the Decreto Único’s reliance framework plus Colombia’s IMDRF affiliate member status (effective September 2025) materially raises Colombia’s strategic value. The five-month Colombian FIH timeline that has been the benchmark for the past three years will compress meaningfully once the Decreto Único is in force.

    The IRB and ethics committee dimension matters more, not less. The MoU does not touch independent ethics committee review. Sponsors gain little if their Argentine site is approved in 62 days and the Colombian ethics committee for a comparable indication takes four months. Operational selection of ethics committees with proven turnaround for the relevant therapeutic area becomes a larger fraction of the timeline gap.

    What To Watch Between Now And September

    Four watch items will determine how much of the MoU’s potential operational value crystallizes in 2026.

    July 17: The WTO comment window on the Decreto Único closes. Industry comment density and the substance of the final text will shape whether reliance is operationally meaningful or a paper provision.

    Late Q3 2026: Implementing language for the MoU. The instrument as signed is a framework. Working-group structure, the first joint technical projects, and any joint training program will signal how seriously both agencies intend to execute on the framework.

    Q4 2026: Decreto Único publication. The 18-month transition period for industry begins on publication. Sponsors should plan for a 2027 implementation horizon for the new Colombian regime.

    2027 onward: First coordinated inspection. If ANMAT and INVIMA execute a coordinated inspection of a sponsor or manufacturer operating in both countries, that becomes the case study that defines the MoU’s operational reality.

    Why This Matters For Operating At Scale In LATAM

    We have been operating multi-country clinical programs in Latin America since 2010. Across 47 first-in-human studies for MedTech, Biopharma, and Radiopharma sponsors, the practical bottleneck in expanding from a single-country trial to a regional program has rarely been regulatory text. It has been the discontinuities between regulators — different document formats, divergent timing assumptions, ethics committees that interpret international guidance differently, and the absence of any structured channel for coordinating safety information when a study runs in parallel in two jurisdictions.

    The MoU is the first instrument in our operating memory that addresses those discontinuities directly. It does not eliminate them. It builds the architecture inside which they can be addressed deliberately, instead of through ad-hoc coordination at ICH meetings.

    For sponsors evaluating LATAM right now, the immediate practical advice is: do not wait. The MoU’s value compounds for sponsors who establish operational presence in both Argentina and Colombia before the implementing language is in place — because those sponsors will be the test cases that shape how the MoU actually works. By the time the framework is mature, the operational advantage will have moved downstream.

    The Bottom Line

    The Argentina-Colombia MoU of June 13, 2026, does not change clinical trial regulation in either country. It changes the operating architecture between them. For multi-country LATAM sponsors, that architecture is the part of the regulatory environment that has been hardest to manage, and it is the part that has been most resistant to structural improvement.

    If your 2026-2027 strategic plan included evaluating LATAM as a multi-country option for an FIH or early-feasibility study, the case just got materially stronger. If your plan did not include LATAM, the regulatory ceiling that previously made multi-country expansion operationally difficult has been formally lifted.

    The two LATAM regulators with the deepest reform agendas in the region just connected their working architecture. The sponsors who move first will define what the connection means.

    bioaccess® is a clinical research organization purpose-built for first-in-human and early-phase studies for MedTech, Biopharma, and Radiopharma startups in Latin America. We have supported 47 FIH programs since 2010 across Argentina, Brazil, Colombia, Mexico, Costa Rica, and Panama. To discuss a multi-country LATAM trial strategy, contact us at info@bioaccessla.com or visit bioaccessla.com/roadmap.

  • 4 Best Practices for EFS Clinical Trials in Argentina

    4 Best Practices for EFS Clinical Trials in Argentina

    Introduction

    Navigating the complexities of early-phase clinical trials in Argentina presents both challenges and opportunities for researchers. With a rapidly evolving regulatory landscape and a significant increase in investment in the research sector, understanding the best practices for executing effective EFS trials is paramount. How can stakeholders ensure compliance while enhancing patient recruitment and fostering local partnerships to optimize trial outcomes?

    This article delves into essential strategies that can help researchers successfully navigate Argentina’s clinical trial environment, ensuring efficient study execution and improved participant engagement. By leveraging insights into the Medtech landscape and addressing key challenges, stakeholders can enhance their approach to clinical research. Collaboration and strategic partnerships will be crucial in driving success in this dynamic field.

    Understand Argentina’s Regulatory Landscape for EFS Trials

    is primarily overseen by the . Researchers must submit a , which includes the study protocol, informed consent forms, and detailed safety data. Familiarity with the , is crucial as it outlines the requirements for . This regulation not only streamlines the approval process but also mitigates risks associated with non-compliance, which can lead to costly delays or trial failures.

    Engaging with can provide invaluable insights and facilitate smoother interactions with ANMAT, enhancing the likelihood of successful submissions. Recent updates to health regulations are expected to improve the efficiency of the approval process, indicating a rising investment in the research sector, which has seen a remarkable 130% increase over the past five years. Understanding ANMAT’s function and the is essential for executing efficient research studies in the country.

    Additionally, leveraging insights from Global Trial Accelerators™ can empower medtech startups to navigate these complexities and optimize their market access strategies. By subscribing to Global Trial Accelerators™, researchers can stay informed about the latest regulatory updates and market access strategies, further improving their chances of success in .

    The central node represents the overall regulatory landscape, while branches show key components and their relationships. Each color-coded branch helps you navigate through the various aspects of the regulatory process.

    Implement Effective Patient Recruitment Strategies in Argentina

    To enhance for the EFS clinical trial Argentina, a multifaceted approach is essential. Involving significantly boosts awareness and establishes trust within . For example, community engagement coordinators have effectively increased inquiries and enrollment by conducting outreach through community clinics and organizing . These efforts build trust and promote participation.

    in outreach. Targeted social media campaigns have generated substantial interest; one study noted a rise in inquiries from 2.15 to 28.07 per month after implementing . Tailoring recruitment messages to reflect and addressing barriers such as language and transportation can further improve participation rates.

    Collaboration with enhances credibility and aids referrals. Partnerships with physical therapy clinics have lessened travel burdens for rural participants, demonstrating the effectiveness of this approach. This comprehensive strategy not only but also ensures that research studies are more representative of the diverse patient populations in the country.

    The central node represents the main goal of enhancing patient recruitment, while the branches show different strategies and their specific actions. Each color-coded branch helps you see how various approaches contribute to the overall success.

    Leverage Local Partnerships for Successful Trial Execution

    Establishing collaborations with nearby hospitals, research institutions, and is crucial for the successful implementation of the EFS in Argentina. These partnerships not only provide access to skilled staff and diverse patient groups but also leverage established infrastructures that enhance study efficiency. For example, regional CROs can expedite and streamline , significantly reducing timelines. In 2022, Argentina hosted 3,935 , underscoring its robust and the effectiveness of regional partnerships.

    Moreover, regional collaborators offer valuable insights into local healthcare practices and patient preferences, which can inform study design and implementation. Engaging with early in the process can facilitate smoother approvals, as the approval period from these committees typically takes about 15 working days. This proactive approach fosters goodwill within the community and enhances the . By prioritizing these collaborations, stakeholders can navigate the complexities of clinical research more effectively.

    The center represents the main idea of local partnerships, while the branches show the benefits and examples of how these collaborations can enhance clinical trial success.

    Align Trial Designs with Local Healthcare Practices

    To enhance the efficiency of the efs Argentina, it is essential to . This alignment considers the . For instance, affect nearly one-third of the adult urban population, highlighting the necessity for that address these regional health challenges.

    Integrating these regional treatment protocols into study designs can significantly improve . Research indicates that when tests reflect the conditions of regional healthcare, participants are more inclined to follow protocols and remain engaged throughout the study. Additionally, adjusting the informed consent procedure to align with regional cultural norms fosters greater understanding and trust among participants, which is crucial for ethical compliance and successful study outcomes.

    Involving during the design phase offers invaluable insights into health needs and preferences. This collaboration not only enhances the relevance of the study but also cultivates a sense of ownership among community stakeholders, leading to improved recruitment and retention rates. For example, initiatives like the Family and Community Health Program demonstrate that incorporating local knowledge into health strategies can yield better health outcomes and participant involvement in research.

    Furthermore, can significantly expedite the testing process, enabling approvals in as few as 4-8 weeks, compared to the 6+ months typically required in the US and EU. This efficiency not only facilitates quicker access to but also results in substantial cost savings-up to $25K per patient-through pre-negotiated site contracts. By leveraging these advantages, the efs can be designed more effectively, ultimately enhancing research and development investments.

    The central node represents the main focus of aligning trial designs. Each branch shows a different factor that influences this alignment, and the sub-branches provide more detailed insights or examples related to those factors.

    Conclusion

    Navigating the landscape of early-phase clinical trials in Argentina demands a strategic approach that encompasses regulatory understanding, patient recruitment, local partnerships, and trial design aligned with healthcare practices. The successful execution of EFS trials relies on strict adherence to regulations set forth by ANMAT, effective engagement with local communities, and the establishment of collaborations that leverage regional insights and resources.

    Key practices such as:

    • Engaging local regulatory consultants
    • Employing targeted patient recruitment strategies
    • Forming partnerships with healthcare institutions
    • Aligning study designs with local health needs

    are essential. These strategies not only enhance the efficiency of clinical trials but also ensure that research reflects the realities of the patient population, ultimately leading to more meaningful outcomes.

    As the clinical trials landscape in Argentina continues to evolve, embracing these best practices can significantly improve the success rates of EFS trials. Stakeholders must prioritize regulatory compliance, foster community relationships, and tailor trial designs to local health challenges. By doing so, researchers can contribute to a robust clinical research environment that advances medical knowledge and enhances patient care in the region.

    Frequently Asked Questions

    What organization oversees the regulatory structure for medical studies in Argentina?

    The regulatory structure for medical studies in Argentina is primarily overseen by the National Administration of Drugs, Food and Medical Technology (ANMAT).

    What is required from researchers when submitting a clinical study in Argentina?

    Researchers must submit a comprehensive clinical study dossier that includes the study protocol, informed consent forms, and detailed safety data.

    Why is familiarity with Disposition 7516/2025 important for researchers?

    Familiarity with Disposition 7516/2025 is crucial as it outlines the requirements for Good Clinical Practice (GCP) compliance, streamlining the approval process and mitigating risks associated with non-compliance.

    How can local regulatory consultants assist researchers in Argentina?

    Engaging with local regulatory consultants can provide invaluable insights and facilitate smoother interactions with ANMAT, enhancing the likelihood of successful submissions.

    What recent trend has been observed in the research sector in Argentina?

    The research sector in Argentina has seen a remarkable 130% increase in investment over the past five years.

    How can Global Trial Accelerators™ benefit medtech startups?

    Leveraging insights from Global Trial Accelerators™ can empower medtech startups to navigate regulatory complexities and optimize their market access strategies.

    What advantage does subscribing to Global Trial Accelerators™ offer researchers?

    Subscribing to Global Trial Accelerators™ allows researchers to stay informed about the latest regulatory updates and market access strategies, further improving their chances of success in clinical studies.

    List of Sources

    1. Understand Argentina’s Regulatory Landscape for EFS Trials
      • bioaccessla.com (https://bioaccessla.com/blog/master-the-anmat-approval-process-for-clinical-trials)
      • institutocer.com.ar (https://institutocer.com.ar/en/blog/argentina,-an-ideal-destination-to-develop-clinical-trials)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/argentina)
      • institutocer.com.ar (https://institutocer.com.ar/en/blog/will-argentina-be-the-next-medtech-clinical-trial-destination-in-latin-america)
    2. Implement Effective Patient Recruitment Strategies in Argentina
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/argentina)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trial-patient-recruitment-services-market/argentina)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC12444702)
    3. Leverage Local Partnerships for Successful Trial Execution
      • clinicaltrialsarena.com (https://clinicaltrialsarena.com/news/clinical-trials-considerations-for-latin-america-5813786-2)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC9858272)
      • meddeviceonline.com (https://meddeviceonline.com/doc/will-argentina-be-the-next-medtech-clinical-trial-destination-in-latin-america-0001)
      • riotimesonline.com (https://riotimesonline.com/argentina-positions-itself-as-international-benchmark-in-clinical-trials)
      • marketdataforecast.com (https://marketdataforecast.com/market-reports/la-contract-research-organization-services-market)
    4. Align Trial Designs with Local Healthcare Practices
      • hia.paho.org (https://hia.paho.org/en/node/159)
      • data.who.int (https://data.who.int/countries/032)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC5523004)
      • data.unicef.org (https://data.unicef.org/country/arg)

  • ICH E6(R3) Annex 2 Just Hit Step 4 In Rio. Argentina Is Positioned To Be Latin America’s First Adopter. Here’s What That Means For Medtech Sponsors.

    On June 3, 2026, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use convened its biannual Assembly in Rio de Janeiro — the first ICH meeting ever held in Latin America. Brazil’s health regulator, ANVISA, hosted. Among the multiple guidelines under consideration at the meeting, only one was advanced to Step 4 — the final stage of ICH adoption: E6(R3) Annex 2, the guideline that codifies decentralized clinical trial design, pragmatic study architectures, digital health technologies, and real-world data as integral elements of GCP-compliant clinical research.

    For a Latin American clinical research operator that has spent the past sixteen years arguing the case to MedTech, biotech, and radiopharma founders, the June 1 to June 4 sequence in Rio is the most strategically significant positioning event of 2026. The geographic precedent is itself meaningful — ICH governance has historically convened in Geneva, Brussels, Tokyo, or other established regulatory capitals. Selecting Rio de Janeiro and partnering with ANVISA as host signals a structural shift in how ICH governance views Latin American regulatory infrastructure. The substantive outcome — only one guideline elevated to Step 4 at the meeting, and that guideline being the one that defines modern trial design — matters even more for how sponsors will think about LATAM site sequencing over the next 18 to 24 months.

    This post unpacks what Annex 2 actually changes, why the Rio venue matters, and how MedTech sponsors should think about Argentina’s position as the first Latin American jurisdiction structurally ready to accept Annex 2-compliant protocols without amendment.

    What ICH E6(R3) Annex 2 Actually Changes

    ICH E6(R3) is the current Good Clinical Practice (GCP) guideline that all major regulators — FDA, EMA, MHRA, PMDA, Health Canada, and adopting regulators in Latin America — converge on for clinical trial conduct. The most recent revision moved GCP to a risk-based, principle-driven model. Annex 2 extends E6(R3) to explicitly cover the trial designs that have become operational reality over the past five years but lacked formal codification in GCP guidance.

    Specifically, Annex 2 addresses:

    • Decentralized clinical trials (DCTs) — trials where participant interaction with study sites is partially or fully replaced by remote visits, home-based assessments, mobile health units, or telehealth consultations.
    • Pragmatic trial designs — protocols built around real-world clinical settings, with broader patient populations and less restrictive inclusion criteria than traditional efficacy trials.
    • Remote site visits — sponsor monitoring conducted through electronic data review, remote source verification, and risk-based on-site oversight rather than universal in-person visits.
    • Digital health technology (DHT) data capture — continuous glucose monitors, wearable cardiac telemetry, accelerometer-based motion data, smartphone-based patient-reported outcomes, and similar tools used as primary or secondary endpoint capture methods.
    • Real-world data (RWD) — use of electronic health records, claims data, registries, and other non-trial sources as supporting evidence within GCP-compliant studies.
    • Adaptive designs — pre-specified protocol modifications based on accumulating trial data, including sample size re-estimation and arm-dropping decisions.

    The substantive shift in Annex 2 is not new regulation. It is the formal incorporation of these design elements into GCP rather than treating them as exceptions that require special justification. For sponsors who have been building modern trial designs over the past five years, the legal architecture finally caught up with the operational reality.

    Why The Rio Venue Matters

    ICH Assembly meetings rotate among the home jurisdictions of ICH members. Hosting the meeting is a substantive role — the host regulator coordinates logistics, sets the agenda for site-specific discussions, and shapes the framing of how the meeting’s outcomes are communicated to global stakeholders. ANVISA hosting the June 2026 Assembly is the strongest signal to date that Brazilian regulatory infrastructure is converging with ICH governance not as an observer but as an active participant.

    For Brazilian sponsors and CROs, the immediate implication is that ANVISA’s preparation for formal E6(R3) adoption is now visible in a way it was not six months ago. The May 28, 2026 ANVISA board session that explicitly addressed ICH E6 and E8 implementation preparation was the first concrete signal. The June 3 Assembly hosting is the next, much stronger signal. Brazilian formal E6(R3) adoption has no publicly announced timeline yet, but the operational trajectory is no longer in doubt.

    For Argentina, the implication is different but equally substantive. Argentina’s ANMAT, under Disposición 7516/25 operative since December 1, 2025, already maintains a regulatory framework aligned with E6(R3) principles. Argentina did not need to host the Rio Assembly to be ready for Annex 2 — it was already there. What the Rio Assembly does for Argentina is confirm that its regulatory positioning was correctly anticipated, and accelerate the speed at which ANMAT can absorb Annex 2-aligned protocols from sponsors.

    Argentina As The First LATAM Annex 2-Ready Jurisdiction

    Disposición 7516/25 modernized Argentina’s clinical trial framework along several dimensions that align directly with E6(R3) principles: a 62-day parallel ethics and agency review pathway, ICH E6(R3) substantive alignment in protocol structure expectations, and operational mechanisms for risk-based monitoring and remote oversight. Critically for Annex 2, Disposición 7516/25 does not preclude decentralized design elements, DHT data capture, or pragmatic patient populations — it accommodates them.

    The practical consequence is that sponsors designing Annex 2-compliant protocols for FDA or EMA submission in 2026 and 2027 do not face a structural barrier to LATAM site inclusion when Argentina is the lead LATAM jurisdiction. Brazil, Colombia, Mexico, and other LATAM regulators have not formally adopted E6(R3), let alone Annex 2 — meaning protocols built around decentralized or DHT-enabled designs face higher regulatory friction in those jurisdictions until each regulator adopts the guidance domestically.

    For Brazil, the trajectory is unambiguous post-Rio. ANVISA hosting the Assembly, the May 28 board session on E6 and E8 preparation, and the substantive operational alignment between ANVISA’s technovigilance and clinical research frameworks all point toward formal E6(R3) adoption in 2026 or 2027. Annex 2 acceptance follows.

    For Mexico (COFEPRIS), Colombia (INVIMA), and other LATAM regulators, the path is less defined. Colombia’s pending Decreto Único de Dispositivos Médicos e In Vitro (currently in WTO comment phase with a July 17 deadline) introduces international reliance pathways that may indirectly accelerate Annex 2 acceptance, but no formal adoption has been signaled.

    Operational Implications For MedTech Sponsors Designing 2026-2027 Protocols

    For a MedTech sponsor designing a protocol today for a 12 to 18 month FIH-to-pivotal sequence, three operational questions matter immediately.

    First, should the protocol be built Annex 2-compliant from the start? The answer is almost always yes if any of the following apply: DHT-collected endpoints are part of the endpoint set; the patient population is large enough that pragmatic design considerations would materially expand enrollment; remote visits or telehealth consultations would meaningfully reduce participant burden; or the trial design contemplates pre-specified adaptive elements such as sample size re-estimation. Building Annex 2-compliant from the start adds modest protocol-authoring effort and substantial future flexibility.

    Second, how should LATAM country sequencing change? For 2026 and through Q2 2027, Argentina-primary is now the recommended LATAM lead jurisdiction for any Annex 2-aligned design. Disposición 7516/25 is the only operative LATAM framework that can absorb the design without amendment. Brazil-secondary is appropriate as ANVISA formalizes its adoption. Mexico and Colombia remain opportunistic, evaluated on therapeutic-area depth and sponsor-specific operational requirements rather than as primary LATAM hubs for decentralized designs.

    Third, what about sponsors with existing LATAM site relationships built around traditional trial architectures? The Annex 2 guidance does not invalidate traditional trial designs. Sponsors running fully on-site, non-decentralized protocols can continue without adjustment. The shift matters for sponsors whose product strategy is built around DHT-collected endpoints or decentralized data capture — for whom the regulatory architecture in LATAM was previously a bottleneck and now is not.

    What Comes Next

    National regulator implementation of E6(R3) Annex 2 will proceed on independent timelines through 2026 and 2027. FDA has signaled implementation guidance is forthcoming. EMA has indicated alignment without formal adoption schedule. PMDA and Health Canada are expected to follow. In Latin America, ANMAT is positioned to be the first formal adopter, followed by ANVISA. The realistic timeline for ANMAT formal Annex 2 acceptance is Q4 2026 to Q1 2027. ANVISA follows in H1 2027 to H2 2027.

    For sponsors making 2026 country sequencing decisions today, the implication is straightforward. Argentina is positioned as the natural lead LATAM jurisdiction for Annex 2-aligned protocols. Brazil follows. Mexico and Colombia continue to be evaluated case-by-case based on therapeutic-area depth and sponsor-specific requirements.

    The Bottom Line

    Latin America is no longer at the edge of global GCP. The June 3 Rio Assembly, the ANVISA hosting of the meeting, and the Step 4 advancement of E6(R3) Annex 2 together signal a structural shift that sponsors building modern trial designs should integrate into 2026-2027 strategy now rather than after the fact.

    The most expensive country sequencing decision is not the one made wrong. It is the one made too late, after the trial design has been frozen and the regulatory pathway is already constrained by choices that no longer reflect the current landscape.

    If you are evaluating an Annex 2-aligned FIH protocol for 2026 or 2027 and want a LATAM country sequencing analysis that integrates the new Rio Assembly outcomes, the team at bioaccess® can produce a tailored proposal within two weeks. We have run first-in-human and pivotal-stage trials across Argentina, Brazil, Colombia, Mexico, and Panama since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Master Radiopharma Clinical Trials in Argentina: Key Strategies and Insights

    Master Radiopharma Clinical Trials in Argentina: Key Strategies and Insights

    Introduction

    The landscape of radiopharmaceutical clinical trials in Argentina is rapidly evolving, driven by an increasing demand for innovative cancer treatments and a robust regulatory framework. These trials leverage radioactive substances for diagnosis and therapy, playing a crucial role in enhancing local healthcare capabilities and contributing to global medical advancements. However, amidst this promising backdrop, challenges such as patient recruitment present significant hurdles for researchers.

    What strategies can be employed to overcome these obstacles and ensure successful participation in these vital studies? Exploring effective approaches and collaboration opportunities may hold the key to unlocking the full potential of radiopharma trials in Argentina. By addressing these challenges head-on, stakeholders can foster a more dynamic clinical research environment that not only benefits patients but also advances the field as a whole.

    Define Radiopharma Clinical Trials and Their Importance in Argentina

    Radiopharmaceutical clinical studies utilize radioactive substances for diagnosis and treatment, playing a pivotal role in oncology. These studies are essential for advancing targeted therapies that effectively combat cancer while minimizing damage to healthy tissues. In Argentina, the expanding infrastructure for nuclear medicine, supported by partnerships like those between CAOIC and CAEME, alongside a rising incidence of cancer – evidenced by 133,420 total cancer cases documented in 2022 – highlights the significance of radiopharma clinical trial Argentina. They not only enrich the global medical knowledge base but also enhance local healthcare capabilities, providing patients with access to innovative treatments.

    Bioaccess’s Global Trial Accelerators™ deliver crucial research insights and market access strategies tailored for medtech startups in Latin America, thereby improving the landscape for radiopharmacy studies. The specialized services offered by Bioaccess include comprehensive regulatory consulting for Lu-177, Ac-225, and Ga-68 radiopharmaceutical clinical studies, ensuring compliance across LATAM markets. Argentina’s evolving regulatory environment, characterized by reforms that have streamlined approval processes since 2017, combined with its cost-effectiveness, makes the country an optimal site for a radiopharma clinical trial Argentina. Successful advancements in treatment outcomes, such as enhanced survival rates and improved quality of life, have been demonstrated through radiopharma clinical trial Argentina, further solidifying the nation’s role in the evolution of cancer care.

    However, challenges related to patient recruitment remain a significant hurdle for clinical research leaders. Creative strategies are essential to attract qualified participants and ensure the success of these studies. How can we overcome these obstacles to enhance participation in clinical research? Collaboration and innovative approaches will be key in addressing these challenges and advancing the field.

    The central node represents the main topic, while the branches show different aspects of radiopharmaceutical clinical trials. Each color-coded branch helps you navigate through the importance, infrastructure, regulatory aspects, and challenges related to these trials.

    Explore Regulatory Framework for Radiopharma Trials in Argentina

    In Argentina, the regulatory framework governing radiopharma clinical trial Argentina is primarily overseen by the National Administration of Drugs, Food and Medical Technology (ANMAT). A pivotal aspect of this framework is the Clinical Trial Authorization (CTA), which must be secured before initiating any radiopharma clinical trial in Argentina. Adhering to Good Clinical Practice (GCP) guidelines is not just a recommendation; it’s essential for ensuring ethical conduct and safeguarding participant safety throughout the research process.

    As we look ahead to 2026, the average approval timeline for clinical studies stands at approximately 70 working days. However, this period can extend to 120 days, depending on the study’s complexity. Moreover, compliance with local regulations regarding individual consent and data protection is mandatory. Understanding the nuances of the ANMAT approval process and engaging early with the agency are crucial for sponsors and contract research organizations (CROs) in the context of the radiopharma clinical trial Argentina. This proactive approach helps in executing studies efficiently, minimizing delays, and upholding the highest standards of patient safety.

    With bioaccess’s comprehensive regulatory consulting services, sponsors can adeptly navigate these complexities. By leveraging insights from the Global Trial Accelerators™, they can enhance their market access strategies and streamline the clinical research process across Latin America. This collaboration is not just beneficial; it’s essential for overcoming the challenges inherent in clinical research.

    This flowchart outlines the steps to follow for conducting radiopharma clinical trials in Argentina. Each box represents a key action or decision point, guiding you through the process from start to finish.

    Implement Effective Strategies for Conducting Radiopharma Trials

    To conduct successful radiopharmaceutical trials, several key strategies should be implemented:

    1. Early Engagement with Regulatory Authorities: Initiating discussions with ANMAT at the outset of the study design process is crucial. This proactive approach clarifies regulatory requirements and streamlines the approval process, ultimately reducing delays.
    2. Site Selection: Selecting sites with proven experience in radiopharmaceuticals and access to treatment-naive patient populations significantly enhances recruitment and data quality. Notably, some clinical research locations demonstrate performance that is several times superior to others, underscoring the importance of strategic site selection.
    3. Training and Protocol Development: Comprehensive training for all staff in handling radioactive materials, coupled with meticulously developed protocols, mitigates risks and ensures compliance with safety regulations. This preparation is essential for preserving the integrity of the examination.
    4. Participant Involvement: Actively engaging individuals in the study process is essential. Clear communication regarding the risks and benefits of participation fosters trust and can lead to improved recruitment and retention rates. Effectively engaging patients not only enhances their experience but also contributes to the overall success of the study.

    By applying these approaches, organizations can manage the intricacies of radioactive drug studies more efficiently, ultimately resulting in improved results and faster timelines.

    The center represents the main goal of implementing effective strategies, while each branch shows a specific strategy. Follow the branches to see how each strategy contributes to the success of radiopharmaceutical trials.

    Leverage Local Expertise: Collaborate with CROs for Success

    Collaborating with local Contract Research Organizations (CROs) like bioaccess® is crucial for the success of radiopharma clinical trial Argentina. With specialized expertise in the regulatory landscape, bioaccess® has streamlined approval processes, leading to quicker participant recruitment. Their comprehensive regulatory consulting services ensure adherence to local regulations, which significantly improves the quality of data collected.

    Research indicates that leveraging local CROs can lead to substantial cost savings – between 40-60% – compared to conducting studies in the US or EU. Moreover, a striking 73% of patients prefer to hear about clinical study opportunities from their healthcare providers. This statistic underscores the vital role of local expertise in recruitment efforts, making it clear that establishing strong partnerships with CROs like bioaccess® not only simplifies the trial process but also boosts the chances of successful outcomes.

    In summary, the collaboration with local CROs is not just beneficial; it is essential for navigating the complexities of the radiopharma clinical trial Argentina. By choosing to partner with bioaccess®, researchers can ensure a more efficient and effective study process, ultimately leading to better patient outcomes.

    The blue slice shows the potential cost savings when working with local CROs, while the green slice represents the percentage of patients who prefer to learn about clinical studies from their healthcare providers. The larger the slice, the more significant the impact!

    Conclusion

    Radiopharmaceutical clinical trials are pivotal for advancing cancer treatment in Argentina, utilizing innovative therapies that specifically target malignancies while minimizing damage to healthy tissue. This field’s growth is essential not only for improving patient care but also for strengthening the nation’s healthcare infrastructure, particularly in light of the rising cancer cases and proactive initiatives by organizations like CAOIC and CAEME. By embracing these trials, Argentina is positioning itself as a leader in oncology, providing patients with access to cutting-edge treatments and contributing to global medical advancements.

    Key strategies have emerged to optimize the execution of radiopharmaceutical clinical trials:

    1. Early engagement with regulatory bodies
    2. Strategic site selection
    3. Comprehensive training
    4. Active participant involvement

    These components can significantly enhance trial outcomes. Moreover, collaboration with local Contract Research Organizations (CROs) such as bioaccess® boosts efficiency and compliance, leading to faster timelines and improved patient experiences. These insights highlight the necessity of a well-structured approach to navigate the complexities of clinical research in this specialized field.

    The importance of mastering radiopharmaceutical clinical trials in Argentina cannot be overstated. As the nation refines its regulatory framework and enhances its research capabilities, stakeholders in the healthcare sector must embrace innovative strategies and foster collaborations that will drive success in clinical research. By prioritizing patient engagement and leveraging local expertise, the potential for breakthroughs in cancer treatment transforms from mere possibility into a promising reality.

    Frequently Asked Questions

    What are radiopharmaceutical clinical trials?

    Radiopharmaceutical clinical trials utilize radioactive substances for the diagnosis and treatment of diseases, particularly in oncology, to advance targeted therapies that effectively fight cancer while minimizing harm to healthy tissues.

    Why are radiopharmaceutical clinical trials important in Argentina?

    They are crucial for enriching the global medical knowledge base and enhancing local healthcare capabilities, providing patients access to innovative treatments, especially as the incidence of cancer rises in the country.

    What is the current cancer incidence in Argentina?

    In 2022, there were 133,420 total cancer cases documented in Argentina.

    How does Bioaccess support radiopharma clinical trials in Argentina?

    Bioaccess’s Global Trial Accelerators™ provide essential research insights and market access strategies for medtech startups in Latin America, along with comprehensive regulatory consulting for specific radiopharmaceutical studies.

    What regulatory changes have occurred in Argentina since 2017?

    Argentina’s regulatory environment has evolved, with reforms that have streamlined approval processes, making it more efficient for conducting radiopharma clinical trials.

    What are some successful outcomes from radiopharma clinical trials in Argentina?

    Successful advancements include enhanced survival rates and improved quality of life for patients undergoing treatment through these trials.

    What challenges do clinical research leaders face in Argentina?

    A significant challenge is patient recruitment, which requires creative strategies to attract qualified participants and ensure the success of clinical studies.

    How can participation in clinical research be enhanced in Argentina?

    Collaboration and innovative approaches are essential to overcome recruitment obstacles and advance the field of clinical research.

    List of Sources

    1. Define Radiopharma Clinical Trials and Their Importance in Argentina
      • journals.lww.com (https://journals.lww.com/eurjcancerprev/fulltext/2026/03000/cancer_mortality_predictions_for_2025_in_latin.1.aspx)
      • aacrjournals.org (https://aacrjournals.org/cancerrescommun/article/5/12/2236/771224/Cancer-Incidence-and-Mortality-Estimates-in-Latin)
      • wcrf.org (https://wcrf.org/preventing-cancer/cancer-statistics/global-cancer-data-by-country)
      • executiveforecast.com (https://executiveforecast.com/conversation/argentinas-clinical-trial-renaissance-interview-with-mariel-peitiado—president-camara-argentina-de-organizaciones-de-investigacion-clinica-caoic-argentina)
      • worldpopulationreview.com (https://worldpopulationreview.com/country-rankings/cancer-rates-by-country)
    2. Explore Regulatory Framework for Radiopharma Trials in Argentina
      • Master ANMAT Clinical Trial Approval in Argentina: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/master-anmat-clinical-trial-approval-in-argentina-a-step-by-step-guide)
      • drugpatentwatch.com (https://drugpatentwatch.com/blog/argentinas-pharmaceutical-crossroads-a-strategic-guide-to-navigating-deregulation-risk-and-radical-opportunity)
      • pubmed.ncbi.nlm.nih.gov (https://pubmed.ncbi.nlm.nih.gov/22262271)
      • linkedin.com (https://linkedin.com/pulse/argentinas-62-day-approval-latam-country-showdown-fih-martinez-clark-t2s6e)
      • linkedin.com (https://linkedin.com/posts/juliomartinezclark_global-trial-accelerators-activity-7444727204200075264-A7MX)
    3. Implement Effective Strategies for Conducting Radiopharma Trials
      • biobostonconsulting.com (https://biobostonconsulting.com/top-5-alarming-statistics-you-must-know-about-clinical-trial-site-selection)
      • Checking your browser – reCAPTCHA (https://pubmed.ncbi.nlm.nih.gov/29394327)
      • novotech-cro.com (https://novotech-cro.com/news/novotech-maps-global-growth-radiopharmaceutical-trials)
    4. Leverage Local Expertise: Collaborate with CROs for Success
      • bioaccessla.com (https://bioaccessla.com/blog/cross-registration-support-in-argentina-and-chile-key-insights-for-clinical-trials)
      • The Growing Role of CROs in Clinical Trials | PPD (https://ppd.com/blog/growing-role-of-contract-research-organizations-in-clinical-trials)
      • novotech-cro.com (https://novotech-cro.com/blog/going-global-how-working-cro-can-benefit-your-clinical-trials)
      • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
      • Latin America CRO Services Market Size & Growth, 2033 (https://marketdataforecast.com/market-reports/la-contract-research-organization-services-market)

  • $8 Billion Of Pharma Capital Just Pointed At Argentina. What Medtech Founders Should Take From The May 29 CAEME Announcement.

    On May 29, 2026, the Cámara Argentina de Especialidades Medicinales (CAEME) announced jointly with President Javier Milei a six-year clinical research investment commitment from seven multinational pharmaceutical companies: Pfizer, Merck, Roche, Novartis, BMS, GSK, and Sanofi. The total commitment is USD 8 billion through 2032. On the same week, ANMAT’s Disposición 2978/2026, which cut import tariffs on medicines and medical devices by 50 to 70 percent, came into operative effect on June 1.

    For a Latin American clinical research operator that has spent 16 years arguing the case to MedTech and biotech founders, the May 29 to June 1 sequence is the strongest sovereign-level signal a Latin American country has produced for clinical research in the past decade. The data and the policy arrived in the same week. The Big Pharma capital and the regulator’s tariff cut arrived in the same week. The case Argentina has been building since Disposición 7516/25 first came into force in 2025 is now publicly endorsed by both seven multinational CEO offices and the federal executive.

    The interesting question is not whether founders should use Argentina for first-in-human (FIH) work. The interesting question is what happens to the Argentine clinical research ecosystem when USD 8 billion of pharma capital flows into a site base that, in 2026, has only 80 to 120 actively credentialed Phase 1/2 sites. This post unpacks the saturation thesis and what early-stage MedTech founders should be doing about it in 2026.

    The Site Saturation Math

    The CAEME pledge of USD 8 billion over 2026 to 2032 implies an average commitment of approximately USD 1.33 billion per year. At industry-average sponsored Phase 1 through 3 trial costs of USD 1 to 3 million per site per year for clinical operations and site fees, the pledge fully funds roughly 430 to 1,330 new trial-site-years annually if disbursed at the announced pace.

    Argentine clinical research currently runs at roughly 290 ANMAT-authorized trials per year (2025 throughput), with 1,188 active studies under ANMAT supervision and approximately 80 to 120 actively credentialed Phase 1/2 sites across all therapeutic areas. The pledge contemplates a 2.5x step-up in trial inflows against approximately the same site base.

    The implication is straightforward. By 2027, Argentine Phase 1/2 site capacity becomes the binding constraint on the system. Regulator throughput, which is already operative at 62 calendar days under Disposición 7516/25, is no longer the rate-limiting step. Site availability is. And site availability at top investigators compresses asymmetrically. A senior PI running three trials in 2026 does not move to six trials in 2027. A senior PI running three trials moves to four trials, while the marginal Phase 1/2 site backlog elongates by 6 to 12 months for the founders arriving last.

    Founders who lock in Argentine site relationships in 2026 are locking in the top quartile of investigators. Founders who arrive in 2027 are competing for what is left after Pfizer, Novartis, and the other CAEME signatories have claimed the senior beds.

    Why the Argentine Government Did This Now

    Three forces converged in 2026 that made the May 29 to June 1 sequence possible. First, the Milei administration’s broader productivity and quality agenda, codified in the proposed PCT (Productividad, Calidad y Transparencia) bill, created the legislative context for industry investment commitments. Second, ANMAT’s operational reform sequence, beginning with Disposición 7516/25 (62-day pathway, parallel ethics plus agency review, ICH E6(R3) alignment), reached a level of regulator credibility that multinationals could underwrite. Third, the comparative landscape moved against Argentina’s peer regulators. Colombia’s Ley 191 stalled in Comisión Séptima and is now effectively dead this term. Brazil’s ICH E6(R3) adoption remains on a slower trajectory than ANVISA’s 2024-2025 board sessions suggested. Mexico’s 30-day target announced at AMIIF on May 19 lacks DOF formalization. Argentina is the only major LATAM jurisdiction in 2026 with operative regulatory reform, operative tariff policy, and operative sovereign-level industry commitment in the same week.

    The PCT bill is the only caveat that matters. The CAEME pledge is contingent on PCT passage. As of June 1, the bill remains stalled. Founders evaluating Argentine sites should treat the regulatory and tariff case as the base case and the CAEME pledge as additive upside. Disposición 7516/25 and Disposición 2978/2026 are in force regardless.

    How to Sequence Argentina in 2026

    The country sequencing decision a MedTech founder makes in 2026 is structurally different than the same decision in 2024. Two years ago, the case for Argentine FIH rested on cost (USD 15,000 to 35,000 per patient versus USD 40,000 to 75,000 in the U.S. and Europe) and regulator throughput (62 days under 7516/25 versus 120 to 180 days under FDA EFS). Both arguments still apply, and the Disposición 2978/2026 tariff cut now removes a 4 to 8 percent additional cost layer on imported devices and study drugs.

    What is new in 2026 is the time pressure. The CAEME pledge does not change the operational case. It changes the urgency of the operational case. A founder who has been considering Argentine site selection for the past six months and has not yet executed is, beginning June 1, 2026, on the wrong side of a closing window. By Q4 2026, the same site relationships will be visibly competitive. By Q2 2027, the top-quartile PI list will be substantively claimed.

    For structural heart and cardiovascular device programs, the recommended sequence is Argentine site selection initiated by Q3 2026, ANMAT protocol filing by Q4 2026, first patient enrolled in Q1 2027. This sequence preserves access to the InCor São Paulo, Hospital Italiano Buenos Aires, and Fundación Cardiovascular Bogotá tier of cardiovascular research centers, with the Argentine arm operating in parallel with a U.S. EFS submission.

    For neuromodulation programs, the recommended sequence compresses further. Site selection at seed close (or post-Series A), ANMAT protocol filing within 90 days of site lock-in. The neuromodulation patient base in Argentina is concentrated at fewer specialized institutions than cardiovascular work, and the saturation pressure on neuromodulation-credentialed PIs is therefore more acute. Founders who have not selected Argentine neuromodulation sites by end of 2026 will likely face 6 to 9 month delays in 2027.

    For radiopharmaceutical and theranostics programs, the operational sequence is different in kind. Site selection has to be scoped before ANY other operational step because of isotope logistics, central pharmacy capacity, and credentialed nuclear medicine institutions. Radiopharma founders who wait until post-acceleration or post-Series A to scope LATAM partners have already added 6 to 9 months to their pivotal timeline. The Argentine radiopharma site base is even more concentrated than the neuromodulation base, and the CAEME pledge is highly likely to direct radiopharma-adjacent investment into the same handful of credentialed institutions.

    What This Means for the Colombia Case

    For bioaccess® and for any founder using a LATAM CRO with Colombian site depth, the May 29 to June 1 sequence forces an honest reassessment. Colombia in 2026 holds the following: established U.S.-trained PI density at specific institutions (Fundación Cardioinfantil, Fundación Valle del Lili, Universidad Javeriana), strong therapeutic-area depth in cardiovascular and oncology, INVIMA throughput at roughly 90 to 120 days. Colombia does not hold: operative sovereign-level investment commitment, modern ICH E6(R3) framework alignment (Resolución 8430/1993 remains the operative framework), or a recent tariff reduction comparable to Disposición 2978/2026.

    The Colombia case for 2026 is no longer “cheaper and faster.” The Colombia case is “specific therapeutic-area depth, U.S.-trained PI networks, and complementarity to an Argentine arm.” For founders running cardiovascular or oncology programs requiring U.S. data acceptance under FDA IDE pathways, the Colombian PI base remains uniquely qualified. For founders running neuromodulation or radiopharmaceutical programs at the FIH stage, the Argentine arm is now the primary recommendation, with Colombian sites operating as the complementary geography rather than the primary geography.

    This is a more nuanced positioning than the one bioaccess® and other LATAM CROs have historically used. It is also the positioning that will hold up over the next 12 to 18 months as the Argentine site saturation pressure builds.

    What Founders Should Do Before End of Q3 2026

    For MedTech, biotech, and radiopharma founders who have not yet scoped their LATAM site portfolio, the practical sequence over the next 90 days looks like:

    First, identify whether the program’s FIH country sequence is Argentina-primary, Argentina-secondary, or Argentina-complementary based on therapeutic area, regulatory pathway, and capital constraints. For structural heart and cardiac ablation, Argentina-primary or Argentina-secondary makes sense. For neuromodulation, Argentina-primary. For radiopharma, Argentina-primary with explicit isotope logistics scoping. For oncology devices with U.S. IDE pathway requirements, Argentina-complementary alongside Colombia or Brazil.

    Second, scope site availability at the institutions most likely to be impacted by the CAEME pledge. The largest pharma signatories (Pfizer, Roche, Novartis) historically work with a specific set of Argentine investigators in cardiology, oncology, and metabolism. Site availability at those investigators will compress first.

    Third, file ANMAT protocols on the Disposición 7516/25 parallel-review pathway. The 62-day timeline allows a 2026 Q3 site selection to produce first-patient-in by year-end. Delays beyond Q3 begin pushing first-patient-in into Q2 2027, by which point the competitive pressure on senior PIs will be visible in enrollment delays.

    Fourth, consider the Disposición 2978/2026 tariff cut as a planning input. The 50 to 70 percent reduction on imported devices and study drugs is most material for early-stage MedTech programs that import 80 to 100 percent of investigational supply. Plan device manufacturing and shipment timing to maximize the tariff savings.

    The Bottom Line

    Argentina did not become a clinical research hub on May 29, 2026. Argentina has been a clinical research hub for 30 years. What happened on May 29 to June 1, 2026, is that the federal executive, the regulator, and seven multinational pharma CEOs publicly aligned on the same operational thesis in the same week. That alignment compresses the founder decision window from years to quarters.

    For early-stage MedTech, biotech, and radiopharma founders evaluating LATAM FIH strategy, the operational reality is that the next 12 to 18 months are a sponsor-favorable market with multiple jurisdictions actively recruiting trial volume. Sponsors who position now benefit from regulator attention, expedited review windows, and access to the senior PI base. Sponsors who delay lose that window.

    The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong country sequence for their specific program. Argentina’s May 29 to June 1 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 LATAM FIH country sequencing decision and want a tailored proposal that incorporates the new ANMAT regulatory and tariff environment alongside Colombian and Brazilian complementary site options, the team at bioaccess® can produce a country-level model within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • 4 Steps to Conduct a Medical Device Study in Argentina

    4 Steps to Conduct a Medical Device Study in Argentina

    Introduction

    Navigating the complexities of conducting a medical device study in Argentina demands a thorough understanding of the country’s regulatory landscape. The National Administration of Drugs, Foods, and Medical Devices (ANMAT) plays a crucial role in overseeing compliance, presenting both opportunities and challenges for researchers aiming for successful outcomes.

    What specific steps must researchers take to not only meet stringent regulations but also streamline the research process and enhance patient recruitment? This guide outlines the essential stages of executing a medical device study, from grasping regulatory requirements to ensuring post-trial compliance, equipping researchers with the knowledge necessary to excel in this dynamic environment.

    Understand the Regulatory Landscape for Medical Devices in Argentina

    Before embarking on a , it is essential to understand the . This knowledge not only ensures compliance but also sets the stage for successful research outcomes. Here’s how to navigate this critical environment:

    1. Research : Start by visiting the to access the most recent regulations and guidelines tailored to medical equipment. It’s vital to pay close attention to how equipment is categorized into four groups (I, II, III, IV) based on their associated risk levels.
    2. Identify Relevant Regulations: Focus on pivotal regulations such as Provision No. 969 (1997) for , Provision No. 9688 (2019) for registration processes, Provision No. 11467 (2024) for , and Provision No. 8194 (2023) for . These documents delineate the necessary for successful registration.
    3. Consult Authorities: Engage with local compliance specialists or legal advisors who specialize in . Their expertise can provide invaluable insights and assist in navigating the complexities of regulatory requirements.
    4. Stay Updated: Given that regulatory frameworks can shift frequently, it’s wise to subscribe to newsletters or join professional organizations that provide updates on policy changes affecting medical equipment in Argentina.

    By thoroughly understanding the regulatory environment, including specific labeling criteria such as the manufacturer’s address, sterilization method, and other essential details, you can effectively prepare for the subsequent steps in your .

    Each box represents a step in the process of understanding regulations for medical devices. Follow the arrows to see the order of actions you should take to ensure compliance and successful research outcomes.

    Register Your Medical Device: Steps and Documentation Required

    To successfully register your in Argentina, follow these essential steps:

    1. Classify Your Equipment: Begin by identifying the classification of your medical equipment according to . This classification is crucial as it dictates the registration pathway and specific requirements.

    2. Prepare Required Documentation: Assemble the necessary documents, which include:

      • Technical File: This document must provide comprehensive evidence of your device’s safety and efficacy.
      • Declaration of Conformity: A formal statement affirming that your equipment complies with all relevant standards.
      • : Proof of adherence to ISO 13485 or equivalent quality standards.
      • : Ensure these materials are in Spanish and meet local regulatory requirements.

    3. Submit Application: Complete the and submit it along with the required documentation to ANMAT. All documents must be translated into Spanish by a certified translator to ensure compliance. The review period for Class I and II items is approximately 15 to 30 working days, while the full registration timeline spans around 60 to 120 working days.

    4. Monitor Application Status: After submission, regularly check the status of your application via ANMAT’s online portal. Be prepared to promptly address any requests for additional information or clarification. The , and manufacturers must conduct revalidation of the device within 30 days from the date of expiry.

    Additionally, consider leveraging the expertise of bioaccess to for rapid market access across Latin America. By accessing over 50 pre-qualified research sites in the region, you can enhance and streamline your research strategies. By diligently following these steps and adhering to the regulations outlined in Disposition 2318/2002 and Disposition 727/2013, you can significantly improve your chances of a successful outcome.

    Each box represents a step in the registration process. Follow the arrows to see how to move from classifying your equipment to monitoring your application status.

    Execute the Clinical Trial: Site Selection and Patient Recruitment Strategies

    Carrying out a successful research study demands careful planning and implementation. To effectively approach and patient recruitment, consider the following:

    1. : Choose with a proven track record in . Key considerations include:

      • Experience: Select sites that have successfully conducted similar studies, ensuring familiarity with specific challenges and requirements.
      • Infrastructure: Confirm that the site is equipped with the necessary facilities and technology to support the experiment effectively.
      • : Ensure the site complies with all regulatory standards and maintains a good standing with ANMAT, which is crucial for smooth operations.

    2. : Develop a comprehensive that encompasses:

      • : Collaborate with local healthcare providers and community organizations to raise awareness about the study, fostering trust and interest among potential participants.
      • : Leverage social media and online platforms to target specific demographics, enhancing outreach and engagement with potential participants.
      • Incentives: Offer incentives for participation, such as travel reimbursements or complimentary health check-ups, to acknowledge participants’ commitment and reduce barriers to enrollment.

    3. Screening and Enrollment: Implement a rigorous to ensure that enrolled patients meet the study criteria. Maintain transparent communication with participants throughout the enrollment process to keep them informed and engaged, which is vital for retention.

    By focusing on strategic and effective patient recruitment, you can significantly improve the quality and efficiency of your in Argentina.

    The central node represents the overall goal of executing a clinical trial, while the branches show the key areas to focus on. Each sub-branch provides specific strategies or considerations that contribute to the success of the trial.

    Conduct Post-Trial Activities: Data Analysis and Reporting Compliance

    After completing your clinical trial, conducting thorough is essential for ensuring compliance and maximizing the impact of your findings. Here’s how to approach and reporting compliance:

    1. : Evaluate the safety and effectiveness of your medical instrument by examining the gathered data. Key considerations include:

      • : Employ appropriate statistical techniques to accurately interpret the data. As Jodi Petersen noted, “Data is the language of the powerholders,” emphasizing the critical role of data in regulatory contexts.
      • : Evaluate results against predefined endpoints to determine the device’s performance.
      • Documentation: Maintain comprehensive documentation of all processes to ensure transparency and reproducibility.

    2. Reporting Compliance: Prepare a detailed report that encompasses:

      • : Summarize results, including any .
      • : Ensure the report aligns with , incorporating necessary appendices or supplementary materials. Familiarity with the registration pathways of ANVISA, INVIMA, and COFEPRIS can significantly enhance your submission process and expedite market access.
      • Publication: Consider publishing your results in a peer-reviewed journal to contribute to the scientific community and enhance the credibility of your findings.

    3. : Utilize insights gained from the experiment to inform future studies and enhance your research processes. Engage with stakeholders to discuss findings and gather constructive feedback.

    By diligently carrying out these , you can ensure adherence to standards and significantly enhance the impact of your clinical trial results. Additionally, with the Final ICH M11 CeSHarP Guideline set for 18.03.2026, staying updated on regulatory changes is vital for successful compliance.

    This flowchart outlines the steps to take after a clinical trial. Start with data analysis, move to reporting compliance, and finally establish a feedback loop to improve future studies.

    Conclusion

    Successfully conducting a medical device study in Argentina is not just a task; it’s a strategic endeavor that demands a comprehensive understanding of the regulatory landscape, meticulous preparation, and strategic execution. By following the outlined steps – from grasping the intricacies of ANMAT regulations to effectively managing clinical trials and post-trial activities – researchers can navigate the complexities of the medical device study process with confidence.

    Key insights emphasized throughout this discussion include:

    • The critical importance of familiarizing oneself with ANMAT guidelines
    • The necessity of thorough documentation for device registration
    • The strategic selection of clinical trial sites and patient recruitment methods

    Each of these steps is crucial for ensuring compliance and maximizing the potential for successful research outcomes.

    Ultimately, the significance of this process extends beyond mere compliance; it’s about contributing valuable innovations to the healthcare landscape in Argentina. Engaging with local experts, staying updated on regulatory changes, and fostering community involvement are all vital components that can enhance the effectiveness of medical device studies. By embracing these practices, researchers can not only achieve their objectives but also support advancements in medical technology that benefit society as a whole.

    Frequently Asked Questions

    What is the role of ANMAT in the regulation of medical devices in Argentina?

    ANMAT, the National Administration of Drugs, Foods, and Medical Devices, governs the regulatory landscape for medical devices in Argentina, ensuring compliance and facilitating successful research outcomes.

    How are medical devices categorized in Argentina?

    Medical devices in Argentina are categorized into four groups (I, II, III, IV) based on their associated risk levels.

    What are some key regulations to be aware of for medical devices in Argentina?

    Important regulations include Provision No. 969 (1997) for clinical trials, Provision No. 9688 (2019) for registration processes, Provision No. 11467 (2024) for safety and performance requirements, and Provision No. 8194 (2023) for good techno surveillance practices.

    Why is it important to consult local compliance specialists or legal advisors?

    Consulting local compliance specialists or legal advisors is crucial as they can provide valuable insights and assistance in navigating the complexities of regulatory requirements for medical equipment in Argentina.

    How can one stay informed about changes in medical device regulations in Argentina?

    Staying informed can be achieved by subscribing to newsletters or joining professional organizations that provide updates on policy changes affecting medical equipment in Argentina.

    What specific labeling criteria should be considered for medical devices in Argentina?

    Specific labeling criteria include the manufacturer’s address, sterilization method, and other essential details necessary for compliance.

    List of Sources

    1. Understand the Regulatory Landscape for Medical Devices in Argentina
      • trade.gov (https://trade.gov/market-intelligence/argentina-medical-products-import-update)
      • artixio.com (https://artixio.com/post/medical-device-regulations-and-registration-process-in-argentina-anmat)
    2. Register Your Medical Device: Steps and Documentation Required
      • mavenprofserv.com (https://mavenprofserv.com/medical-devices-registration-in-argentina)
      • linkedin.com (https://linkedin.com/posts/chenran818_anmat-argentina-medical-device-registration-activity-7349467593583316994-tU65)
      • omcmedical.com (https://omcmedical.com/argentina-medical-device-registration)
      • trade.gov (https://trade.gov/healthcare-resource-guide-argentina)
    3. Execute the Clinical Trial: Site Selection and Patient Recruitment Strategies
      • statsmarketresearch.com (https://statsmarketresearch.com/download-free-sample/8070364/global-patient-recruitment-for-clinical-trials-forecast-market)
      • proximacro.com (https://proximacro.com/news/5-key-strategies-for-clinical-trial-patient-recruitment)
      • subjectwell.com (https://subjectwell.com/seven-essential-strategies-to-revolutionize-your-patient-recruitment)
      • Patient Recruitment Strategies for Trials | CCRPS (https://ccrps.org/clinical-research-blog/patient-recruitment-strategies-for-clinical-trials)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/argentina)
    4. Conduct Post-Trial Activities: Data Analysis and Reporting Compliance
      • FDA Issues Guidance on Modernizing Statistical Methods for Clinical Trials (https://fda.gov/news-events/press-announcements/fda-issues-guidance-modernizing-statistical-methods-clinical-trials)
      • gmp-compliance.org (https://gmp-compliance.org/gmp-news/fda-guidance-on-statistical-methods-for-clinical-trials)
      • coresignal.com (https://coresignal.com/blog/data-science-quotes)
      • nisum.com (https://nisum.com/nisum-knows/must-read-inspirational-quotes-data-analytics-experts)